Infectious Disease

Infectious Disease-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View List View Download All PDFs Archive

loading
NEW Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
May 25, 2017 - N°20170145417

The invention provides novel immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit or suppress tlr-mediated signaling in response to a tlr ligand or tlr agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, ...
Dosage and administration of non-fucosylated anti-cd40 antibodies
Seattle Genetics, Inc.
May 18, 2017 - N°20170137528

This invention relates methods of using a non-fucosylated anti-cd40 antibody for treatment of cancer and chronic infectious diseases.
Ctla4 binders
Seattle Genetics, Inc.
May 18, 2017 - N°20170137521

The present invention provides molecules, such as isvds and nanobodies, that bind to ctla4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules ...
Infectious Disease Patent Pack
Download 152+ patent application PDFs
Infectious Disease Patent Applications
Download 152+ Infectious Disease-related PDFs
For professional research & prior art discovery
inventor
  • 152+ full patent PDF documents of Infectious Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Pd1 and/or lag3 binders
Seattle Genetics, Inc.
May 18, 2017 - N°20170137517

The present invention provides molecules, such as isvds and nanobodies, that bind to pd1 and lag3 and, optionally to human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious ...
Antibodies to il-15
Calypso Biotech Sa
May 18, 2017 - N°20170137511

The present invention relates to antibodies binding il-15, in particular humanized antibodies. In particular, the anti-il-15 antibodies according to the invention are able to neutralize il-15 activity and are useful in the prevention and/or treatment of an autoimmune disease and/or inflammatory disorder, a malignancy, transplant rejection, metabolic condition and/or an infectious disease caused by parasitic, viral or ...
System for implanting, activating, and operating an implantable battery
Ortho-ion Ltd.
May 18, 2017 - N°20170136236

Apparatus, systems, and methods for the treatment of bone, cartilage and other types of hard tissue. The treatments, which are suitable for extended treatment, include the treatment and prevention of pathologies through the controllable use of silver, iron, zinc, or magnesium ions. These pathologies may include a pathology which is at least partially induced or aggravated by an infectious disease, ...
Infectious Disease Patent Pack
Download 152+ patent application PDFs
Infectious Disease Patent Applications
Download 152+ Infectious Disease-related PDFs
For professional research & prior art discovery
inventor
  • 152+ full patent PDF documents of Infectious Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Bacteriophage and antibacterial composition comprising the same
Cj Cheiljedang Corporation
May 11, 2017 - N°20170128504

The present invention relates to a novel bacteriophage having a specific bactericidal activity against salmonella, a composition for the prevention or treatment of infectious diseases comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, an animal feed or drinking water comprising the bacteriophage as an active ingredient, and a sanitizer or cleaner comprising ...
System and method for preventing transfer of infectious disease
Cj Cheiljedang Corporation
May 04, 2017 - N°20170124850

A system and method to assist in the prevention of the transfer of infectious diseases. More particularly, a system and method that monitors and alerts caregivers to cleanse, sanitize, and/or wash their hands prior to engaging with other individuals in their care. The disclosed technology includes beacons in wireless communication with a mobile computing device, such as a smart ...
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
Immutep
May 04, 2017 - N°20170119876

The present invention relates to the use of a recombinant lag-3 or derivatives thereof in order to boost a monocyte-mediated immune response, in particular to elicit an increase in the number of monocytes in blood. This finds use in the development of novel therapeutic agents for the treatment of an infectious disease or cancer.
A method for the treatment of glioblastoma with wharton jelly-mesenchymal stem cells (wj-msc) derived from ...
Immutep
May 04, 2017 - N°20170119824

The embodiments of the present invention provide a method for the treatment of glioblastoma using wharton jelly-mesenehmal stem cells (wj-msc) derived from human umbilical cord. The mesenchymal stem cells have potential to inhibit the glioblastoma cancer cells. For isolating the msc, the donor is screened for infectious diseases. The consent from the donor is taken for the collection of the ...
Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
Immutep
May 04, 2017 - N°20170119770

And salts thereof in which r1, r2, r3, r4, x, y and n have the meanings given in the specification, are inhibitors of trk kinases and are useful in the treatment of diseases which can be treated with a trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
Lanthionine synthetase c-like 2-based therapeutics
Biotherapeutics, Inc.
May 04, 2017 - N°20170119762

Provided are compounds that target the lanthionine synthetase c-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.
Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
Biotherapeutics, Inc.
April 27, 2017 - N°20170114069

And salts thereof in which r1, r2, r3, r4, x, y and n have the meanings given in the specification, are inhibitors of trk kinases and are useful in the treatment of diseases which can be treated with a trk kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
Infectious Disease Patent Pack
Download 152+ patent application PDFs
Infectious Disease Patent Applications
Download 152+ Infectious Disease-related PDFs
For professional research & prior art discovery
inventor
  • 152+ full patent PDF documents of Infectious Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Programmable universal cell receptors and method of using the same
Sorrento Therapeutics, Inc.
April 27, 2017 - N°20170112878

The present invention provides programmable universal cell receptors (pucrs) comprising a catalytic antibody region, a transmembrane domain and a cytoplasmic domain. The pucrs disclosed herein may be conjugated to a specificity agent in order to program the receptor for specificity to any molecule of interest. Also provided are nucleic acids encoding such pucrs, and cells expressing the pucrs. Such cells ...
Macrocyclic compounds as trk kinase inhibitors
Array Biopharma, Inc.
April 27, 2017 - N°20170112842

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a, r3, r3a, and z are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
Methods for detecting a biomarker by alternating current electrokinetics
University Of Tennessee Research Foundation
April 20, 2017 - N°20170108493

Methods are described for detecting pathogens, infectious diseases, and physiological conditions by quantifying change of impedance over time of when a biological sample is applied onto a lab-on-a-chip. The lab-on-a-chip utilizes alternating-current electrokinetic (acek) phenomena such that molecules move or are carried in an electric field generated by the application of an electrical signal of predetermined magnitude and frequency to ...
Chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious ...
National University Of Singapore
April 20, 2017 - N°20170107491

The invention provides a chimeric receptor comprising nkg2d, dap10 and cd3 zeta. Also disclosed is a composition comprising this chimeric receptor and methods for making and using it to enhance the cytotoxicity and antitumor capacity of nk cells. The invention also encompansses methods for use of nkg2d-dap10-cd3 zeta polypeptides, vectors and cells in methods for treating cancer ...
Macrocyclic compounds as trk kinase inhibitors
Array Biopharma, Inc.
April 20, 2017 - N°20170107232

Compounds of formula i: and pharmaceutically acceptable salts thereof, wherein ring a, ring b, w, m, d, r2, r2a r3 and r3a are as defined herein, are inhibitors of trk kinases and are useful in the treatment of pain, cancer, inflammation, neurodegenerative diseases and certain infectious diseases.
Compounds useful as immunomodulators
Bristol-myers Squibb Company
April 20, 2017 - N°20170107202

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
University Of Connecticut Health Center
April 13, 2017 - N°20170100455

The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (hsp) preparation or an α-2-macroglobulin (α2m) preparation with a non-vaccine treatment modality. In particular, an hsp preparation or an α2m preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or ...
Pharmaceutical compositions comprising danirixin for treating infectious diseases
Glaxosmithkline Intellectual Property (no. 2) Limited
April 13, 2017 - N°20170100385

Provided are compounds and pharmaceutically acceptable salts thereof, and combinations of compounds, their pharmaceutical compositions, their methods of preparation, and methods for their use in treating or preventing infectious disease.